In a report issued on March 15, Brian Abrahams from RBC Capital maintained a Hold rating on Corbus Pharmaceuticals (CRBP), with a price target of $2.00. The company’s shares closed last Tuesday at $2.18, close to its 52-week low of $0.91.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 8.4% and a 47.7% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Intra-Cellular Therapies, and Karyopharm Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Corbus Pharmaceuticals with a $2.26 average price target, which is a -4.2% downside from current levels. In a report issued on March 15, Roth Capital also maintained a Hold rating on the stock with a $1.79 price target.
See today’s analyst top recommended stocks >>
Corbus Pharmaceuticals’ market cap is currently $195.8M and has a P/E ratio of -1.30. The company has a Price to Book ratio of 6.70.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.
